Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Boehringer and Elanco pick up two accolades each in the Animal Pharm Awards 2017

Boehringer Ingelheim Animal Health's transformational year and Elanco's product developments have both been commended as part of the annual Animal Pharm Awards

Elanco secured two awards for new products in 2017, while Boehringer claimed awards for best European company and inspirational chief executive. All of 2017's award winners are listed below.

Best new companion animal product 2017 – Galliprant

This award is an accolade for two companies for shaking up the canine pain management market in the US. Galliprant (grapiprant tablets) was developed by Aratana Therapeutics and is sold via a co-commercialization deal by Elanco.

Last year's winners

Click here to see the winners of last year's Animal Pharm Awards, including Aratana Therapeutics, Zoetis, Ceva Santé Animale, Chanelle and others.

The product was introduced to the US market in January 2017 as a first-in-class targeted tool for the management of pain and inflammation associated with canine osteoarthritis. Galliprant is the first and only EP4 receptor antagonist available in veterinary medicine.   

It stood out in a crowded and highly competitive market of over 15 nonsteroidal anti-inflammatory drugs. Elanco and Aratana expect this product to become a market leader in pain management – a position it is already well on its way to achieving. 

Not only has the product excelled, its commercialization is an example of one of the industry's leading players combining with an agile start-up to bring innovation to market – something that could become a blueprint for future animal health licencing deals.

Elanco said Galliprant has exceeded its goals on market penetration, top line sales, net sales and re-order rate.  

In 2017, the product received a positive opinion ruling in Europe. This was followed by European approval this year.

Best new food animal product 2017 – Clynav

The second award for Elanco's product portfolio goes to its Clynav fish vaccine – the first DNA vaccine to be approved in Europe for any species.

The judging panel selected this first-in-class vaccine, which is used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3). Clynav gained approval for the vaccine in Europe and Canada last year.

Clynav is the first nucleic acid vaccine available for protection against pancreas disease in Atlantic salmon. It provides a reduction in the negative effects on daily weight gain and mortality, in addition to cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with SAV3.

Not only does this award highlight the ongoing growth of vaccines as important products in animal health but it also shows how key aquaculture biologicals will be, as feeding a growing global population puts a higher demand on the production of fish.

Elanco acquired a significant amount of assets in the aquaculture health space when it purchased Novartis Animal Health. Now, the firm is working to turn some embryonic Novartis R&D projects into commercialization. Being a first-mover in fish DNA vaccines could be key for the company as it looks to be the market leader in this space.

Best start-up – ViroVet

While ViroVet was a previous winner of this award in 2015, the company has snapped up the accolade again.

In 2015, the Belgian firm's business concept and initial R&D work impressed the judging panel. This time around, the company's expertise in securing a significant series A funding round backed its nomination.

Clinvet and Nutriad sponsor Animal Pharm Awards

Contract research organization Clinvet and animal feed additive specialist Nutriad are the sponsors of the Animal Pharm Awards 2017.

clinvet logo

Clinvet was established in 1999 and specializes in conducting laboratory and field-based clinical trials to evaluate the safety, metabolism and efficacy of veterinary health products. Clinvet is based in South Africa and Morocco.

A group of affiliated companies enables the firm to provide a wide range of services in support of laboratory and clinical trials performed on veterinary health products.

With a wealth of experience, Clinvet has for many years been able to support leading veterinary health pharmaceutical companies in ground-breaking research and development programs. Conducting pivotal trials required for the registration of health products worldwide also forms part of Clinvet's portfolio.

Nutriad has been a manufacturer of state-of-the-art feed additives for more than 50 years. The company aims to be its customers' first choice in palatability, mycotoxin management and digestive performance in poultry, swine, cattle, companion animals and aquaculture.

nutriad logo

The Dendermonde-headquartered firm is active in more than 80 countries and serves a wide range of customers, including farmers, integrators, veterinarians and feed mills. The company's expertise stretches from developing nations in Asia and Latin America to more established markets in Europe and North America.

Nutriad was recently acquired by French animal feed additives specialist Adisseo.

Clinvet and Nutriad have no say in the outcome of the awards. Their sponsorship also has no bearing on their own nominations for any awards.

In the last 12 months, ViroVet achieved first and second closing of a series A round. The company raised around €6.8 million ($8.3 million). Among animal health start-ups, especially in Europe, this was no mean feat.

ViroVet claims to be the first company to be developing a new generation of vaccines based on plasmid-launched live attenuated viruses, as well as the first firm to develop antiviral medicines for livestock.

Under the guidance of its chief executive, Erwin Blomsma, the company has become a leading voice in the animal health industry with regards to innovation and championing the plight of smaller firms. ViroVet's stature belies its pre-revenue ranking.

Also in 2017, ViroVet extended its vaccine pipeline to the small ruminant sector by collaborating with GALVmed.

Best company in Europe – Boehringer Ingelheim Animal Health

In 2017, all eyes were on Boehringer after a game-changing merger with Merial was finalized in the first week of the year.

The company is now the largest animal health firm based in Europe and is intent on becoming the market leader in several more markets around the globe.

The deal for Merial was transformational, making Boehringer the world leader for antiparasitics and vaccines. With the addition of Merial, Boehringer's portfolio is now 81% focused on preventative products such as vaccines or antiparasitics. This is a significant statistic with regards to an industry that is leaning ever more closely to preventative measures over treatments.

The acquisition has seen Boehringer contribute to the closest leadership race in the animal health market for a long while – a positive sign for an industry witnessing many growth trends.

Now, Boehringer has created a platform for it to expand even further into animal health – where the two individual companies could not go individually. Expansion geographically has been mooted, while the firm will also be looking to innovate both internally and through strategic partnerships.

The German company gave an insight into the Merial merger and its future plans when Animal Pharm visited its headquarters last year.

Best company in North America – Prevtec Microbia

Prevtec Microbia is proof you do not have to be one of the industry's big players to win an Animal Pharm award. The Montreal-based business has built a portfolio of innovative vaccines, which are now on sale around the world.

In fact, Prevtec is the first Canadian company to win Animal Pharm's accolade of best North American company.

The company's plan is to develop and commercialize alternatives to antibiotics in the form of veterinary vaccines – something it acted on significantly during 2017.

Last year, the firm received its second product approval in Europe, bagged funding, secured Elanco as its exclusive distributor in Canada and broke into the Russian animal health market.

Additionally, Prevtec manufactured and delivered the first million doses of its Coliprotec F4/F18 vaccine for the European market – a noteworthy feat for any company in the crucial growth area of biologicals.

The company is currently seeking distribution partners to take its vaccines to an even wider global customer base.

Best company in Latin America – Labyes

In Latin America, another one of animal health's up-and-coming companies was commended.

Labyes secured double-digit growth last year as it targeted niche, underserved areas in the region's companion animal market. The Argentine company has built a name for itself as a leader in the ophthalmic and geriatric pet space for Latin America.

Not only is Buenos Aires-headquartered Labyes building a name for itself in Latin America but 2017 also saw the business expand its international activities, with antiparasitic lines being launched in the Middle East and south east Asia.

One of these products – Canis – is the first and only spot-on antiparasitic for dogs that contains praziquantel. The company believes this approach provides a unique solution in terms of scope and effectiveness.

To aid its international growth, Labyes has appointed a director for its newly-added Mexican unit and a sales manager who will focus on markets outside Latin America.

Founded in 1985, the firm aims to become a leading player in companion animals across emerging markets by offering a relatively small portfolio of specialized products.

Last year, the firm spoke to Animal Pharm about its history and future aspirations.

Best company Asia and Australasia – Jinyu Bio-technology

For a second year in a row, China Jinyu Bio-technology has secured this accolade.

The company impressed the judging panel with its achievements in the field of veterinary vaccines. Jinyu has boosted its domestic product portfolio through several approvals, progressed several clinical trials and bolstered its intellectual property.

However, it is the scope of Jinyu's international aspirations that has set itself aside from its Chinese competitors and many other Asian animal health businesses.

Last year, the firm continued to focus on its strategy of internationalization. This has been reflected in recent financial performances, especially in 2017.

Jinyu has begun exporting its products to Mongolia and Kyrgyzstan. Meanwhile, the firm has started registrations in South Korea, Vietnam, Thailand and Japan.

However, one of the company's most notable steps came in July last year when it established a research laboratory in the US. The firm's new subsidiary Jinyu North American Biotechnology was formed to build the research lab, as well as the company's M&A platform overseas. Jinyu also became the first Chinese company to be a member of the Kansas City Animal Health Corridor.

As well as signing a host of R&D deals with partners in China and abroad, Jinyu also purchased 46.96% of the stock equity in Liaoning Yikang – a deal that further bolstered its vaccine capabilities domestically.

Last year, Jinyu told Animal Pharm about its plans for M&A in the companion animal space.

Best company in India/Middle East/Africa – Globion

Indian firm Globion's strategy to target growth in the veterinary vaccines market impressed the judging panel.

Founded in 2006, Hyderabad-based Globion is specifically focused on developing poultry vaccines to global standards. The company stands out in a market that is heavily weighted towards generics.

Globion has a state-of-the-art vaccine manufacturing facility complying with GMP standards that produces its GlobiVac brand.

Lifetime achievement award

This year's Animal Pharm Lifetime Achievement Award goes to Virbac's chairman Éric Marée as he retires from his role.

Last year, the firm's GlobiVac IBHK and GlobiVac ND Unique grew the company's market share of the domestic poultry vaccine sector.

GlobiVac IBHK is for the vaccination of chicks from day one against Inclusion Body Hepatitis-Hydropericardium Syndrome, as well as the vaccination of parent stock for the prevention of vertical transmission of Fowl Adeno Virus type 4 and the protection of chicks by transfer of maternal antibodies from parents.

The company said the syringability and uniform distribution of antigen in Globivac IBHK makes puts the vaccine in an advantageous position compared to its competitors. The product is gaining market acceptance at a very fast rate and is on its way to becoming a top-selling product.

GlobiVac ND Unique is for the protection of chicks from day one against Newcastle disease. It can be delivered through drinking water, a nasal drop or spray.

Globion expects this vaccine to be a strong contender as a market leader, due to the stability of the virus in drinking water at a high temperature when compared to conventional Newcastle disease vaccines, as well as its enterotropic nature that elicits strong local immunity in the gut.

Visionary CEO – Joachim Hasenmaier

In tandem with Boehringer's award for best European company, the firm's leader has also snared an accolade.

Joachim Hasenmaier has led Boehringer's animal health unit into a new era through its largest ever acquisition. He has fronted the business at a crucial time in its history as it implemented an exhaustive integration.

Last year, he spoke exclusively to Animal Pharm about his thoughts on the company's transformation. Dr Hasenmaier noted: "There is a Greek word – Kairos – meaning the right moment in time. That's what we've done. We have seized the right moment in time."

Elsewhere, he represented the company at events in the UK and China. At the latter, Dr Hasenmaier outlined Boehringer's plans to increase its presence in one the key growth geographies in animal health.

Dr Hasenmaier has been in his current role since 2012 and was previously the firm's vice president animal health from 2002 to 2011. Prior to joining Boehringer, he held managerial roles at Intervet and Hoechst.

Throughout 2017, Dr Hasenmaier has enhanced his reputation as a key opinion leader by representing Boehringer in his confident and honest manner.

Best contract research organization – Triveritas

In 2017, Triveritas managed to expand its business globally to six continents ensuring its brand is one of the most recognized among animal health contract research organizations (CROs).

In particular, the company spent a lot of time last year growing its presence in the North American clinical development market. Triveritas is attempting to bring its expertise in regulatory, clinical, chemistry and manufacturing controls, toxicology, biologicals, pharmacovigilance and quality assurance to a broader client base.

Triveritas is the only animal health CRO located in the EU and the US with "the presence and expertise to develop veterinary medicinal products for both markets".

During the year, the company worked on over 170 new projects and enquiries across a host of companion animal and food-producing species. Triveritas increased its customer base by more than 25% in 2017 to just under 100 clients.

Currently, the firm has active projects for clients based in Australia, Belgium, Brazil, Canada, Chile, Germany, Ireland, Spain, Finland, France, Hungary, Israel, Italy, Japan, Netherlands, Norway, Sweden, Switzerland, Turkey, South Korea, the UK and the US.

Importantly, its clients have a re-order rate of more than 95%. Over the course of 2017, Triveritas also delivered training to more than 200 individuals in the areas of good clinical practice, vaccine development, companion animal medicines and regulatory affairs.

Interestingly, Triveritas doubled its transatlantic studies conducted under a single protocol and worked on studies in some crucial next-generation areas of animal health such as monoclonal antibodies and non-surgical treatments for surface cancers.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts